DTR.CN Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: July 10, 2025
Report Source: 2025 1st Quarter Report
Diagnostear Technologies Inc. Stock Analysis DTR.CN
DiagnosTear Technologies, Inc. is an ophthalmic company, which engages in the developing and commercializing disruptive diagnostic solutions for better management of eye diseases. The company is headquartered in Rehovot, Central(Hamerkaz). The company went IPO on 2024-12-09. The firm develops the TeaRx™ technology, a tear‑fluid analytical platform designed for identifying and monitoring front‑of‑the‑eye diseases. The company focuses on research and development of diagnostic tests, clinical validation activities, regulatory readiness, and establishing production capabilities, supported partly through government‑funded research and development(R&D) programs. The firm operates through a single reportable segment dedicated to tear‑based ophthalmic diagnostic solutions, including test development, production line preparation, commercialization planning, and ongoing enhancement of its technological capabilities.
Read More Diagnostear Technologies Inc (DTR.CN) Chart
Key Statistics of Diagnostear Technologies Inc (DTR.CN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
CAD0.45Volume
4050.00P/E Ratio (TTM)
-52 Week Range
Market Cap
19.71MAvg. Volume
31.66KDividend Yield
-Financial Metrics & Statements of Diagnostear Technologies Inc (DTR.CN)
FAQ's for Diagnostear Technologies Inc (DTR.CN)
- According to Musaffa’s Shariah screening methodology, Diagnostear Technologies Inc (DTR.CN) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.